Ekso Bionics Holdings, Inc. (NASDAQ:EKSO), a robotic exoskeleton
company, today announced that the company and its collaborators
will exhibit their Ekso GT robotic exoskeleton in New Orleans at
both the American Academy of Physical Medicine and
Rehabilitation (AAPM&R) Annual Assembly taking place October
20-23, 2016 and the American Medical Rehabilitation Providers
Association (AMRPA) Annual Educational Conference taking
place October 24-26, 2016.
Ekso Bionics will host a symposium in conjunction with
AAPM&R on Friday, October 21 from 4:45 – 6:00 pm at the New
Orleans Downtown Marriott Convention Center. During this
symposium, Dr. Jeffrey Oken, Chief Medical Officer at Marianjoy
Rehabilitation Hospital and Dr. Christina Kwasnica, Medical
Director of Neuro-rehabilitation at Barrow Neurological Institute
will discuss their research on the use of Ekso GT. In
addition, Leslie VanHiel, DPT and Clinical Training Specialist at
Ekso Bionics will review the most recent studies involving the Ekso
GT device. A demonstration and Q&A will follow the
symposium.
There are four educational sessions at AAPM&R dedicated to
robotic therapy:
Session 401. Integrating Advanced Rehabilitation
Technology and Robotics into Clinical Practice
7:30 AM–9:00 AM Oct 20, 2016; Convention Center, Meeting Room
R08-09, Level 2
Erin Eggebrecht, PT, DPT, NCS
Deborah Gaebler-Spira, MD, McGaw Medical Center of Northwestern
University (RIC) PM&R Program
Joshua Vova, MD
Session W204. Incorporating Exoskeletal Robots Into
Practice
2:00 PM–3:30 PM Oct 20, 2016; Convention Center, Meeting
Room 217, Level 2
Lauri Bishop, PT, DPT
Alberto Esquenazi, MD, Chmn Dept of PMR and Chief Med Off at
Moss Rehab Hosp
Kristen Hohl, MD
Casey Kandilakis, PT, DPT, NCS
Donald Leslie, MD, Shepherd Ctr
Joel Stein, MD, Chair at Columbia Univ Med Ctr
Session 223. Frontiers in Rehabilitation
Robotics
2:30 PM–4:00 PM Oct 22, 2016; Convention Center, Great
Hall B, Level 1
Sunil Agrawal, PhD
Ethan Rand, MD, Assistant Professor at New York Prebyterian -
Weill Cornell Medicine
Joel Stein, MD,Chair at Columbia Univ Med Ctr
Session 225. Robotics in Rehabilitation: Optimizing
Treatment Delivery
4:15 PM–5:45 PM Oct 22, 2016; Convention Center, Great Hall B,
Level 1
Alberto Esquenazi, MD, Chmn Dept of PMR and Chief Med Off at
Moss Rehab Hosp
Matthew Vnenchak, PT
The following educational session will be offered at AMRPA:
Robotics in Neurorehabilitation: A Way to Improve Care
Intensity and Efficiency
4:50 PM-5:50 PM Oct. 24, 2016; Royal Sonesta Hotel, Royal Conti
Room
Alberto Esquenazi, MD, Chmn Dept of PMR and Chief Med Off at
Moss Rehab Hosp
Ekso Bionics will be exhibiting at booth numbers 201 for
AAPM&R and 18 for AMRPA.
About Ekso Bionics® Ekso Bionics is a leading
developer of exoskeleton solutions that amplify human potential by
supporting or enhancing strength, endurance and mobility across
medical, industrial and defense applications. Founded in 2005, the
company continues to build upon its unparalleled expertise to
design some of the most cutting-edge, innovative wearable robots
available on the market. Ekso Bionics is the only exoskeleton
company to offer technologies that range from helping those with
paralysis to stand up and walk, to enhancing human capabilities on
job sites across the globe, to providing research for the
advancement of R&D projects intended to benefit U.S. defense
capabilities. The company is headquartered in the Bay Area and is
listed on the Nasdaq Capital Market under the symbol EKSO. For more
information, visit: www.eksobionics.com.
About Ekso™ GT
Ekso™ GT is the first
FDA cleared exoskeleton cleared for use with stroke
and spinal cord injuries from L5 to C7. The Ekso GT with
smart Variable Assist™ (marketed as SmartAssist outside the U.S.)
software is the only exoskeleton available for rehabilitation
institutions that can provide adaptive amounts of power to either
side of the patient’s body, challenging the patient as they
progress through their continuum of care. The suit’s patented
technology provides the ability to mobilize patients earlier, more
frequently and with a greater number of high intensity steps. To
date, this device has helped patients take more than 55 million
steps in over 120 rehabilitation institutions around the world.
Forward-Looking Statements Any statements
contained in this press release that do not describe historical
facts may constitute forward-looking statements. Forward-looking
statements may include, without limitation, statements regarding
(i) the plans and objectives of management for future operations,
including plans or objectives relating to the design, development
and commercialization of human exoskeletons, (ii) a projection of
financial results, financial condition, capital expenditures,
capital structure or other financial items, (iii) the Company's
future financial performance and (iv) the assumptions underlying or
relating to any statement described in points (i), (ii) or (iii)
above. Such forward-looking statements are not meant to predict or
guarantee actual results, performance, events or circumstances and
may not be realized because they are based upon the Company's
current projections, plans, objectives, beliefs, expectations,
estimates and assumptions and are subject to a number of risks and
uncertainties and other influences, many of which the Company has
no control over. Actual results and the timing of certain events
and circumstances may differ materially from those described by the
forward-looking statements as a result of these risks and
uncertainties. Factors that may influence or contribute to the
inaccuracy of the forward-looking statements or cause actual
results to differ materially from expected or desired results may
include, without limitation, the Company's inability to obtain
adequate financing to fund the Company's operations and necessary
to develop or enhance our technology, the significant length of
time and resources associated with the development of the Company's
products, the Company's failure to achieve broad market acceptance
of the Company's products, the failure of our sales and marketing
organization or partners to market our products effectively,
adverse results in future clinical studies of the Company's medical
device products, the failure to obtain or maintain patent
protection for the Company's technology, failure to obtain or
maintain regulatory approval to market the Company's medical
devices, lack of product diversification, existing or increased
competition, and the Company's failure to implement the Company's
business plans or strategies. These and other factors are
identified and described in more detail in the Company's filings
with the SEC. To learn more about Ekso Bionics please visit us
at www.eksobionics.com. The Company does not undertake to
update these forward-looking statements.
Media Contact:
Carrie Yamond/Rajni Dhanjani
212-867-1788
cyamond@lazarpartners.com
Investor Contact:
Debbie Kaster
415-937-5403
investors@eksobionics.com
Ekso Bionics (NASDAQ:EKSO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Ekso Bionics (NASDAQ:EKSO)
Historical Stock Chart
From Apr 2023 to Apr 2024